Angle teams up with Myriad Genetics on cancer patient blood testing
Angle PLC on Wednesday said it has agreed to collaborate with Utah, US-based molecular diagnostic testing and precision medicine firm Myriad Genetics Inc on the testing of blood samples from cancer patients.
The Guildford, England-based liquid biopsy company said that, under the terms of the partnership deal, blood samples from cancer patients will be processed by Angle. The firm’s Parsortix system will be used to capture and harvest intact cancer cells for downstream molecular analysis.
Results from this analysis will then be matched to patient tissue samples using Myriad’s existing tissue-based assay.
Other details of the agreement between the two companies are confidential, Angle said.
‘We are delighted to be working with Myriad Genetics, a major player in tissue-based companion diagnostic tests, seeking to extend their tests to work on a simple blood test using CTCs harvested by the Parsortix system,’ said Chief Executive Officer Andrew Newland.
‘We look forward to working with Myriad Genetics to progress this collaboration which has the potential to have a substantial impact on patient treatment by improving access to actionable genomic data.’
Shares in Angle were up 7.8% at 6.20 pence in London on Wednesday afternoon. The stock remains down 55% over the past year.
Copyright 2025 Alliance News Ltd. All Rights Reserved.